{"id":3544,"date":"2014-10-27T14:29:06","date_gmt":"2014-10-27T12:29:06","guid":{"rendered":"http:\/\/blog.startups.ch\/fr\/?p=3544"},"modified":"2014-10-27T14:29:06","modified_gmt":"2014-10-27T12:29:06","slug":"startup-abionic-sassure-chf-3-8-millions","status":"publish","type":"post","link":"https:\/\/blog.startups.ch\/fr\/2014\/10\/27\/startup-abionic-sassure-chf-3-8-millions\/","title":{"rendered":"La startup \u201cAbionic\u201d s\u2019assure CHF 3.8 Millions"},"content":{"rendered":"<p><strong>Abionic boucle sa deuxi\u00e8me ronde de financement avec succ\u00e8set s\u2019assure 3.8 Millions de nouveaux moyens. Le capital obtenu va \u00eatre investi pour la finition d\u2019un nouvel appareil de diagnostic d\u2019allergies.<\/strong><!--more--><\/p>\n<p><strong>\u00a0<a href=\"https:\/\/i0.wp.com\/blog.startups.ch\/fr\/wp-content\/uploads\/2014\/06\/Fotolia_60242457_S.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-3311\" src=\"https:\/\/i0.wp.com\/blog.startups.ch\/fr\/wp-content\/uploads\/2014\/06\/Fotolia_60242457_S.jpg?resize=689%2C291\" alt=\"Namo Media\" width=\"689\" height=\"291\" srcset=\"https:\/\/i0.wp.com\/blog.startups.ch\/fr\/wp-content\/uploads\/2014\/06\/Fotolia_60242457_S.jpg?w=689&amp;ssl=1 689w, https:\/\/i0.wp.com\/blog.startups.ch\/fr\/wp-content\/uploads\/2014\/06\/Fotolia_60242457_S.jpg?resize=300%2C126&amp;ssl=1 300w\" sizes=\"(max-width: 689px) 100vw, 689px\" data-recalc-dims=\"1\" \/><\/a><\/strong><\/p>\n<p><strong>Sur la voie du succ\u00e8s<\/strong><\/p>\n<p>Abionic a \u00e9t\u00e9 cr\u00e9\u00e9e en 2010 en tant que Spin-off \u00e0 l\u2019EPFL Lausanne. Depuis, Abionic a pu amasser la somme de CHF 3.5 Mio. lors d\u2019une premi\u00e8re ronde de financement et ainsi promouvoir le d\u00e9veloppement d\u2019abioSCOPE et abioDisc. Parall\u00e8lement, la conformit\u00e9 au march\u00e9 europ\u00e9en (l\u2019\u00e9tiquetage CE) a \u00e9t\u00e9 obtenue. Le capital fraichement acquis a aussi \u00e9t\u00e9 utilis\u00e9 pour avancer d\u2019un pas et mener \u00e0 bien la commercialisation sur le march\u00e9 am\u00e9ricain (autorisation FDA 510k), afin de garantir un d\u00e9but d\u2019ann\u00e9e 2015 pleins de succ\u00e8s.<\/p>\n<p>abioSCOPE est un instrument de mesure qui atteint des tr\u00e8s hauts niveaux de l\u2019\u00e9valuation de la sensibilit\u00e9 (au niveau mol\u00e9culaire) gr\u00e2ce \u00e0 une des plus nouvelles nanotechnologies optiques. Cette technologie permet de diagnostiquer facilement les allergies et favorise les entretiens m\u00e9dicaux personnalis\u00e9s. Une petite goutte de sang d\u2019un patient suffit \u00e0 \u00e9tablir un examen complet de ses allergies. abioDISC sert de plateforme de diagnostic, sur laquelle 8 capsules diff\u00e9rentes peuvent \u00eatre positionn\u00e9es. Les capsules contiennent plusieurs biocapteurs \u00e0 nanofluide, qui sont aptes \u00e0 d\u00e9terminer la plupart des allergies. Abionic cr\u00e9\u00e9 un avantage comparatif en combinant une haute pr\u00e9cision, une manipulation facile et une production \u00e0 moindre frais d\u2019abioSCOPE.<\/p>\n<p>Les fondateurs Dr. Nicolas Durand (CEO), Dr. Iwan M\u00e4rki (CTO) et Prof. Theo Lasser (pr\u00e9sident du Conseil d\u2019Administration) ont d\u00e9j\u00e0 gagn\u00e9 20 startups Awards avec Abionic, entre autres le STARTUPS.CH AWARD en 2010. On attend avec beaucoup d\u2019impatience l\u2019entr\u00e9e d\u2019abioSCOPE sur le march\u00e9 en 2015 et nous esp\u00e9rons qu\u2019Abionic continue sur la route ascendante du succ\u00e8s.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abionic<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false}}},"categories":[1],"tags":[],"jetpack_publicize_connections":[],"aioseo_notices":[],"views":1695,"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7y0qY-Va","_links":{"self":[{"href":"https:\/\/blog.startups.ch\/fr\/wp-json\/wp\/v2\/posts\/3544"}],"collection":[{"href":"https:\/\/blog.startups.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.startups.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.startups.ch\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.startups.ch\/fr\/wp-json\/wp\/v2\/comments?post=3544"}],"version-history":[{"count":1,"href":"https:\/\/blog.startups.ch\/fr\/wp-json\/wp\/v2\/posts\/3544\/revisions"}],"predecessor-version":[{"id":3545,"href":"https:\/\/blog.startups.ch\/fr\/wp-json\/wp\/v2\/posts\/3544\/revisions\/3545"}],"wp:attachment":[{"href":"https:\/\/blog.startups.ch\/fr\/wp-json\/wp\/v2\/media?parent=3544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.startups.ch\/fr\/wp-json\/wp\/v2\/categories?post=3544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.startups.ch\/fr\/wp-json\/wp\/v2\/tags?post=3544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}